![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
In recent years ABO incompatible kidney transplantation (KTx) has become a more or less clinical routine procedure with graft and patient survival similar to those of ABO compatible transplants. Antigen-specific immunoadsorption (IA) for anti-A and anti-B antibody removal constitutes in many centers an important part of the treatment protocol. ABO antibody titration by hemagglutination is guiding the treatment; both if the recipient can be transplanted as well as in cases of suspected rejections if antibody removal should be performed. Despite the overall success of ABO incompatible KTx, there is still room for improvements and an extension of the technology to include other solid organs. Based on an increased understanding of the structural complexity and tissue distribution of ABH antigens and the fine epitope specificity of the ABO antibody repertoire, improved IA matrices and ABO antibody diagnostics should be developed. Furthermore, understanding the molecular mechanisms behind accommodation of ABO incompatible renal allografts could make it possible to induce long-term allograft acceptance also in human leukocyte antigen (HLA) sensitized recipients and, perhaps, also make clinical xenotransplantation possible.
| ABBREVIATIONS | ||
| Ab | = | antibody |
| ABOi | = | blood group ABO incompatible |
| AMR | = | antibody-mediated rejection |
| DD | = | diseased donor |
| DFPP | = | double filtration plasmapheresis |
| EC | = | endothelial cells |
| Gb4Cer | = | GalNAcβ3Galα4Galβ4Glcβ1Ceramide |
| Gb5Cer | = | Galβ3GalNAcβ3Galα4Galβ4Glcβ1Ceramide |
| IA | = | immunoadsorption |
| KPD | = | kidney paired donation |
| KTx | = | kidney transplantation |
| LD | = | live donor |
| LTx | = | liver transplantation |
| mAb | = | monoclonal antibody |
| Tx | = | transplantation |